Avantor reported third‑quarter 2025 financial results, showing net sales of $1.6238 billion, a 5.3 % decline from the $1.71 billion reported in Q3 2024. The decline was driven by a 6.4 % drop in Laboratory Solutions revenue to $1.0965 billion and a 2.9 % drop in Bioscience Production revenue to $527.3 million.
The company posted a net loss of $711.8 million, reversing a $57.8 million profit in the same quarter a year earlier. A $785 million goodwill impairment charge on the Distribution reporting unit was the primary driver of the loss.
Adjusted earnings per share were $0.22, below the consensus estimate of $0.23, and adjusted EBITDA was $267.9 million, representing a 16.5 % margin. Adjusted EBITDA margin guidance for the full year was lowered to 16.5 %–17 %, down from the prior 17.0 %–17.5 % range.
Management cut fiscal‑2025 adjusted EPS guidance to $0.88–$0.92, and reiterated a $400 million cost‑transformation program under the “Avantor Revival” plan, which focuses on go‑to‑market optimization, manufacturing investment, portfolio scrutiny, cost savings, and talent development.
The company also highlighted ongoing debt reduction, reporting $1.3 billion of debt paid down in 2024, and authorized a $500 million share‑repurchase program. Net leverage remained at 3.1×, and free cash flow was $171.7 million.
Management attributed the revenue decline to weaker customer activity, production challenges, and competitive pricing pressures, while noting that the goodwill impairment was partly driven by a sustained decline in the company’s share price. The company is pursuing the Avantor Revival plan to address operational inefficiencies and regain market share.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.